Edition:
United States

People: Alexion Pharmaceuticals Inc (ALXN.O)

ALXN.O on Nasdaq

119.26USD
24 Mar 2017
Change (% chg)

$-1.00 (-0.83%)
Prev Close
$120.26
Open
$120.94
Day's High
$121.43
Day's Low
$118.73
Volume
1,292,350
Avg. Vol
2,542,478
52-wk High
$162.00
52-wk Low
$109.12

Bell, Leonard 

Dr. Leonard Bell, M.D., is no longer Chairman of the Board of Alexion Pharmaceuticals, Inc., with effect from May 10, 2017. Dr. Bell was the principal founder of Alexion in 1992 and served as the Chief Executive Officer from the Company's inception until he retired as CEO on March 31, 2015. Under his leadership Alexion grew to become a global biopharmaceutical company with employees serving patients with severe and life-threatening disorders in 50 countries through fully integrated research, discovery, development, manufacturing, and commercial capabilities. Prior to founding Alexion, Dr. Bell was an attending physician at Yale-New Haven Hospital and Assistant Professor of Medicine and Pathology at the Yale University School of Medicine, where he also received his M.D. degree. Dr. Bell was a recipient of the numerous awards and honors as an academic scientist prior to founding Alexion. Dr. Bell received his A.B. from Brown University and M.D. from Yale University School of Medicine. Dr. Bell is currently an Adjunct Assistant Professor of Medicine and Pathology at the Yale University School of Medicine.

Basic Compensation

Total Annual Compensation, USD 358,308
Restricted Stock Awards, USD 5,083,030
Long-Term Incentive Plans, USD --
All Other, USD 19,477,000
Fiscal Year Total, USD 24,918,400

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Leonard Bell

24,918,400

David Brennan

321,991

David Anderson

--

Clare Carmichael

5,142,900

John Moriarty

5,084,410

Martin Mackay

4,679,990
As Of  30 Dec 2015